1. Home
  2. RANG vs TVRD Comparison

RANG vs TVRD Comparison

Compare RANG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANG
  • TVRD
  • Stock Information
  • Founded
  • RANG 2024
  • TVRD 2017
  • Country
  • RANG United States
  • TVRD United States
  • Employees
  • RANG N/A
  • TVRD N/A
  • Industry
  • RANG
  • TVRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • RANG
  • TVRD Health Care
  • Exchange
  • RANG Nasdaq
  • TVRD Nasdaq
  • Market Cap
  • RANG 165.2M
  • TVRD 166.5M
  • IPO Year
  • RANG 2024
  • TVRD N/A
  • Fundamental
  • Price
  • RANG $10.13
  • TVRD $25.61
  • Analyst Decision
  • RANG
  • TVRD Strong Buy
  • Analyst Count
  • RANG 0
  • TVRD 1
  • Target Price
  • RANG N/A
  • TVRD $39.00
  • AVG Volume (30 Days)
  • RANG 15.6K
  • TVRD 39.1K
  • Earning Date
  • RANG 01-01-0001
  • TVRD 05-21-2025
  • Dividend Yield
  • RANG N/A
  • TVRD N/A
  • EPS Growth
  • RANG N/A
  • TVRD N/A
  • EPS
  • RANG N/A
  • TVRD N/A
  • Revenue
  • RANG N/A
  • TVRD N/A
  • Revenue This Year
  • RANG N/A
  • TVRD N/A
  • Revenue Next Year
  • RANG N/A
  • TVRD N/A
  • P/E Ratio
  • RANG N/A
  • TVRD N/A
  • Revenue Growth
  • RANG N/A
  • TVRD N/A
  • 52 Week Low
  • RANG $9.91
  • TVRD $8.14
  • 52 Week High
  • RANG $10.64
  • TVRD $31.32
  • Technical
  • Relative Strength Index (RSI)
  • RANG N/A
  • TVRD N/A
  • Support Level
  • RANG N/A
  • TVRD N/A
  • Resistance Level
  • RANG N/A
  • TVRD N/A
  • Average True Range (ATR)
  • RANG 0.00
  • TVRD 0.00
  • MACD
  • RANG 0.00
  • TVRD 0.00
  • Stochastic Oscillator
  • RANG 0.00
  • TVRD 0.00

About RANG Range Capital Acquisition Corp. Ordinary Shares

Range Capital Acquisition Corp is a blank check company.

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: